Cargando…
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764437/ https://www.ncbi.nlm.nih.gov/pubmed/35059318 http://dx.doi.org/10.3389/fonc.2021.796625 |
| _version_ | 1784634165436612608 |
|---|---|
| author | Yuan, Min Zhu, Zhongzheng Mao, Wei Wang, Hui Qian, Hong Wu, Jianguo Guo, Xianling Xu, Qing |
| author_facet | Yuan, Min Zhu, Zhongzheng Mao, Wei Wang, Hui Qian, Hong Wu, Jianguo Guo, Xianling Xu, Qing |
| author_sort | Yuan, Min |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8764437 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87644372022-01-19 Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study Yuan, Min Zhu, Zhongzheng Mao, Wei Wang, Hui Qian, Hong Wu, Jianguo Guo, Xianling Xu, Qing Front Oncol Oncology Frontiers Media S.A. 2022-01-04 /pmc/articles/PMC8764437/ /pubmed/35059318 http://dx.doi.org/10.3389/fonc.2021.796625 Text en Copyright © 2022 Yuan, Zhu, Mao, Wang, Qian, Wu, Guo and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Yuan, Min Zhu, Zhongzheng Mao, Wei Wang, Hui Qian, Hong Wu, Jianguo Guo, Xianling Xu, Qing Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title | Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title_full | Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title_fullStr | Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title_full_unstemmed | Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title_short | Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study |
| title_sort | corrigendum: anlotinib combined with anti-pd-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764437/ https://www.ncbi.nlm.nih.gov/pubmed/35059318 http://dx.doi.org/10.3389/fonc.2021.796625 |
| work_keys_str_mv | AT yuanmin corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT zhuzhongzheng corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT maowei corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT wanghui corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT qianhong corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT wujianguo corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT guoxianling corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy AT xuqing corrigendumanlotinibcombinedwithantipd1antibodiestherapyinpatientswithadvancedrefractorysolidtumorsasinglecenterobservationalprospectivestudy |